Brief: Nanexa Announces Preclinical Results For Semaglutide Formulation
27/01/2026 07:33
Jan 27 (Reuters) - Nanexa AB NANEXA.ST: ANNOUNCES EXCEPTIONAL PRECLINICAL RESULTS FOR SEMAGLUTIDE FORMULATION STUDIES SHOW EXTRAORDINARY PK PROFILE FOR MONTHLY SEMAGLUTIDE DOSING IMPROVED TOLERABILITY LINKED TO BETTER ADHERENCE IN GLP-1 THERAPIES Source text: ID:nMFN9WxlPm Further company coverage: NANEXA.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com;))
Recent news on Nanexa AB
See all newsNanexa shares soar on €1.17 billion Novo Nordisk deal for injection technology
Brief: Nanexa And Novo Enter Global License, Collaboration Deal
Brief: Forge Nano And Nanexa To Develop Gmp-Compatible Ald Manufacturing Equipment
Brief: Nanexa Q2 Revenue Amounted To SEK 1.7 Million
Sweden's Nanexa Q1 revenue falls, loss widens